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Summary
Novel therapies with unique new targets are needed for patients who are
relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is
a first-in-class, once-daily, oral covalent inhibitor of Bruton tyrosine kinase,
which is overexpressed in the myeloma stem cell population. This study
examined various doses of ibrutinib  low-dose dexamethasone in patients
who received ≥2 prior lines of therapy, including an immunomodulatory
agent. Daily ibrutinib  weekly dexamethasone 40 mg was assessed in 4
cohorts using a Simon 2-stage design. The primary objective was clinical
benefit rate (CBR; ≥minimal response); secondary objectives included
safety. Patients (n = 92) received a median of 4 prior regimens. Ibruti-
nib + dexamethasone produced the highest CBR (28%) in Cohort 4
(840 mg + dexamethasone; n = 43), with median duration of 92 months
(range, 30–147). Progression-free survival was 46 months (range, 04–
173). Grade 3–4 haematological adverse events included anaemia (16%),
thrombocytopenia (11%), and neutropenia (2%); grade 3–4 non-haemato-
logical adverse events included pneumonia (7%), syncope (3%) and urinary
tract infection (3%). Ibrutinib + dexamethasone produced notable
responses in this heavily pre-treated population. The encouraging efficacy,
coupled with the favourable safety and tolerability profile of ibrutinib, sup-
ports its further evaluation as part of combination treatment.
Keywords: multiple myeloma, ibrutinib, dexamethasone, Bruton tyrosine
kinase.
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Meeting and the 2015 Lymphoma & Myeloma
Congress and as a poster presentation at the
2015 International Myeloma Workshop.
The management of relapsed or relapsed and refractory mul-
tiple myeloma (RRMM) has changed considerably in the last
decade, and there have been significant improvements with
regards to patient outcomes. One reason behind these
improvements is the incorporation of novel drugs with
unique mechanisms of action into the treatment armamen-
tarium, which until then, included the use of alkylating
agents, corticosteroids, anthracyclines and autologous stem
cell transplantation (Dimopoulos et al, 2015a). The most
notable classes of new drugs include immunomodulatory
agents (IMiDs) and proteasome inhibitors (PIs). Despite
these improvements, most patients with multiple myeloma
(MM) will ultimately relapse; therefore, agents with novel
targets must be identified and explored to be used either as
single agents or in combination with standard backbone
therapies (Cottini & Anderson, 2015). Thus, MM remains
one of the most significant areas of unmet medical need
among lymphoid malignancies. In addition, the treatment of
patients with RRMM is further complicated by advanced age,
comorbidities (i.e., diabetes, cardiovascular and/or lung dis-
ease), residual toxicities from prior treatments (i.e., periph-
eral neuropathies, myelosuppression) and end-organ damage
resulting from the underlying disease (Dimopoulos et al,
2015a; Nooka et al, 2015).
The B-cell receptor-signalling pathway has emerged as a
new therapeutic target in B-cell malignancies, including MM.
Within this pathway, Bruton tyrosine kinase (BTK) plays a
central role in the activation of downstream pathways associ-
ated with survival and proliferation of B cells (Anderson
et al, 1996; Craxton et al, 1999; Petro et al, 2000; Petro &
Khan, 2001; Buggy & Elias, 2012). It is expressed in >85% of
tumour cells from MM patients, may help regulate myeloma
stemness in the bone marrow of MM patients (Yang et al,
2015), and may play a role in treatment-resistant MM cells
(Tai & Anderson, 2012). Ibrutinib is a first-in-class, potent,
once-daily, orally administered, covalently binding inhibitor
of BTK and is indicated for the treatment of patients with
mantle cell lymphoma who have received ≥1 prior therapy,
marginal zone lymphoma who require systemic therapy and
have received ≥1 prior anti-CD20–based therapy, chronic
lymphocytic leukaemia including patients with chronic lym-
phocytic leukaemia with 17p deletion, and Waldenstr€om
macroglobulinaemia (Pharmacyclics, 2017). Ibrutinib was
designed as a selective inhibitor of the BTK protein and,
in vitro, inhibits BTK activity and induces apoptosis in
human B-cell lymphoma cell lines (Pan et al, 2007; Honig-
berg et al, 2010). Furthermore, ibrutinib decreased MM-
induced bone destruction and suppressed tumour growth in
an in vivo mouse model (Tai & Anderson, 2012). Myeloma
regimens are commonly augmented with dexamethasone
(dex), which often improves response rates to other agents
(Sonneveld & Broijl, 2016). BTK expression was upregulated
at both the protein and mRNA levels in MM1R dex-resistant
cells, suggesting a possible role of BTK in the mechanism of
dex resistance (Chauhan et al, 2002).
This study was designed to assess the efficacy and safety of
ibrutinib, a new agent with a novel mechanism of action,




This study was approved by the Institutional Review Board
at all participating sites, and all patients provided written
informed consent. Key inclusion criteria included measur-
able, symptomatic MM according to International Myeloma
Working Group (IMWG) criteria (Durie et al, 2006); RRMM
after receiving ≥2 lines of therapy (including a PI or IMiD),
including lack of response or disease progression (according
to IMWG response criteria; Rajkumar et al, 2014) to the
most recent line of therapy; and Eastern Cooperative Oncol-
ogy Group (ECOG) performance status ≤1. Key exclusion
criteria were an absolute neutrophil count <075 9 109/l;
platelet count <50 9 109/l; creatinine level >221 lmol/l;
peripheral neuropathy grade ≥2; and a need for concomitant
warfarin or other vitamin K antagonists or strong CYP3A4/5
inhibitors (Indiana University Department of Medicine
2016).
Study objectives
The primary objective was to determine the efficacy of ibruti-
nib, both as a single agent and in combination with dex, in
patients with RRMM, as measured by the clinical benefit rate
[CBR; ≥minimal response (MR)]. Secondary objectives
included duration of clinical benefit, overall response rate
(ORR), duration of response, and safety; exploratory objec-
tives were progression-free survival (PFS), time to progres-
sion and overall survival (OS).
Study design and treatment plan
PCYC-1111 (NCT01478581) was a phase 2, open-label, non-
randomized, multicohort, multicentre, Simon 2-stage study
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of daily ibrutinib with or without weekly dex in RRMM.
Protocol amendment 1 was designed to further explore the
optimal regimen by increasing doses of ibrutinib and/or by
combining it with low-dose (LD) dex. Cohorts 1 and 3
assessed activity of ibrutinib monotherapy (420 and 840 mg/
day, respectively, with 40 mg of dex once weekly allowed on
disease progression at the discretion of the investigator);
Cohorts 2 and 4 assessed ibrutinib (560 and 840 mg/day,
respectively) in combination with 40 mg of oral dex once
weekly (LD dex). The LD dex selected for this study corre-
sponds to that typically used when given weekly in combina-
tion with other agents. The use of LD dex was established in
combination with lenalidomide in a study that demonstrated
superior safety and improved outcomes when compared with
high-dose dex (Rajkumar et al, 2010). An interim analysis
was built into the study, if the enrolment targets were met
after the pre-specified Simon 2-stage expansion criteria. In
Stage 1, up to 18 patients could be enrolled into Cohorts 2,
3 and 4. If ≥3 patients with CBR were observed in Cohorts
2, 3 or 4 then, for Stage 2, the cohort(s) could be selected
for expansion up to a total of 43 patients or until ≥8 patients
with CBR were observed, whichever occurred first.
Study assessments
Patients had scheduled study visits on days 1, 2, 8 15, and 22
of Cycle 1. Thereafter, study visits occurred once per 28-day
cycle on day 1 (2 days), continuing until Cycle 12 unless
otherwise indicated. After Cycle 12, study visits occurred
once every 2 cycles. Adverse events (AEs), ECOG perfor-
mance status and blood samples for haematology and serum
chemistry were collected at each study visit or as needed
based on physician discretion. Myeloma-specific assessments,
including serum protein electrophoresis, urine protein elec-
trophoresis, and/or serum free light-chain assay and quanti-
tative immunoglobulins, were obtained at the beginning of
each treatment cycle to evaluate response.
CBR was defined as the proportion of patients who
achieved stringent complete response, complete response,
very good partial response, partial response (PR), or MR, as
assessed by the modified IMWG response criteria (Rajkumar
et al, 2011); patients were evaluated for response starting at
Cycle 2 and required 2 consecutive assessments to confirm
response. Assessments for response included M-protein
(serum protein electrophoresis, urine protein electrophoresis,
serum immunofixation electrophoresis and serum free light-
chain assay), plasmacytoma evaluations and serum chemis-
tries (e.g., calcium and albumin), with bone radiological
examinations, bone marrow aspiration and biopsy performed
when clinically indicated. Patients could continue to receive
ibrutinib until progressive disease (PD), unacceptable toxicity
or other protocol-specified reason.
Treatment-emergent AEs were coded using the MedDRA
System Organ Class and Preferred Term (https://www.medd
ra.org. Last accessed 30 October 2017); the frequency,
severity, and relationship to the study drug were assessed by
the investigator. All reported treatment-emergent AEs
described are included regardless of investigator attribution.
Study investigators assessed the occurrence of AEs and seri-
ous AEs at all patient evaluation time points during the
study, and AEs were graded according to National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 40 (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_
403_2010-06-14_QuickReference_5x7.pdf). All AEs and
serious AEs were recorded, including duration, severity, sus-
pected relationship to the study drug and any actions taken.
The AE reporting period began with the first dose of study
drug and ended 30 days after the last dose of study drug.
Patient follow-up
For safety, each patient was followed for 30 (7) days after
the last dose of ibrutinib or until the start of a subsequent
antineoplastic therapy, whichever came first. Patients who
discontinued study treatment for reasons other than PD were
followed approximately every 2 months until PD or the start
of subsequent antineoplastic therapy. Once patients pro-
gressed or started use of a subsequent anticancer therapy,
they were contacted for long-term follow-up every 3 months
to assess survival, the use of subsequent antineoplastic ther-
apy, and other malignancies, until last active patient discon-
tinued study treatment.
Data analysis
The primary end point of the study was CBR, defined as the
proportion of patients achieving an MR or better as assessed
by investigator per modified IMWG criteria (Durie et al,
2006; Anderson et al, 2008). The primary efficacy analysis
was performed on the all-treated population. CBR and its
corresponding 2-sided 90% exact binomial confidence inter-
val (CI) were calculated. Cohort 1 was planned to enrol with
a target size of 35 patients if ≥2 patients with CBR were
observed among the first 11 patients. This cohort was
designed to test the null hypothesis that the CBR is ≤10%
versus the alternative hypothesis of ≥30%, at a 1-sided alpha
of 5% with 85% power. Cohorts 2, 3 and 4 were planned
with a sample size of up to 43 patients if ≥3 patients with
CBRs were observed among the first 18 patients in the
cohort, with 80% power and the alternative hypothesis of
CBR rate ≥25%. The primary analysis was performed based
on the assigned cohort treatment and does not include the
response after the addition of dex for patients in Cohorts 1
and 3.
PFS was defined as the duration from start of the treat-
ment to PD or death (regardless of cause of death), which-
ever came first. Kaplan-Meier methods were used to estimate
event-free survival curves and corresponding quartiles (in-
cluding the median). A 2-sided 95% CI was provided for the
median PFS.
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Results
Patient characteristics
Ninety-two patients with RRMM were enrolled between 20
March 2012 and 19 September 2014. Cohort 4 (ibrutinib
840 mg + LD dex) met the pre-specified Simon 2-stage
expansion criteria, and enrolled a total of 43 patients. Med-
ian age was 62–66 years among the 4 cohorts; with the
exception of cytogenic differences that were determined
locally and difficult to interpret because of small sample size,
patient baseline disease characteristics were similar between
cohorts (Table I). Prior treatment exposure patterns changed
as subsequent cohorts were enrolled (Table II). All patients
had received prior steroid treatment, and prior treatment
exposure changed between groups; for example, Cohorts 3
and 4 had more patients who received prior carfilzomib and
pomalidomide given their increasing use in this setting since
study initiation. In addition, 13% of patients were previously
exposed to a monoclonal antibody. Overall, patients had
received a median of 35 prior regimens (range, 2–14). In
cohort 4, 70% were refractory to their last line of therapy; of
these patients, 70% received either a PI or IMiD in that line,
and 58% were dual refractory (PI and IMiD). Median fol-
low-up at the time of analysis was 23 months.
Overall response
The rate of stable disease (SD) stabilization or response
increased with dose (Table III). The highest CBR was
observed in Cohort 4 (28%), including 2 PRs and 10 MRs,
with median duration of 92 months (range, 30–147). An
additional 23% of patients had SD ≥4 cycles, despite patients
actively progressing at the time of enrolment. In the 25
patients (58%) who were dual refractory in Cohort 4, 4
patients (16%) achieved an MR, with an additional 5
patients (20%) maintaining SD ≥4 cycles. Cohort 3 had 33%
SD and no responses.
Progression-free survival
Median time of PFS of each cohort is shown in Fig 1. Com-
pared with Cohorts 1–3 [Cohort 1, 09 months (range, 05–
360+); Cohort 2, 37 months (range, 08–83); Cohort 3,
Table I. Patient characteristics.
Characteristic Cohort 1 (n = 13) Cohort 2 (n = 18) Cohort 3 (n = 18) Cohort 4 (n = 43) Overall (N = 92)
Median age – years (range) 62 (49–74) 66 (46–77) 66 (54–81) 65 (43–81) 65 (43–81)
Male – n (%) 8 (62) 9 (50) 13 (72) 26 (60) 56 (61)
ECOG PS – %
0 54 33 44 47 45
1 46 67 56 53 55
Median time since diagnosis – years 3.9 5.0 6.3 6.5 5.9
Measurable disease – n (%)
SPEP/UPEP 11 (85) 14 (78) 16 (89) 33 (77) 74 (80)
sFLC 2 (15) 4 (22) 2 (11) 10 (23) 18 (20)
Disease status to last treatment* – n (%)
Relapsed 4 (31) 2 (11) 4 (22) 13 (30) 23 (25)
Relapsed and refractory 9 (69) 16 (89) 13 (72) 30 (70) 68 (74)
Last line of therapy – n (%)
PI and/or IMiD 11 (85) 14 (78) 13 (72) 39 (91) 77 (84)
No PI or IMiD 2 (15) 4 (22) 5 (28) 4 (9) 15 (16)
Chromosomal abnormalities by FISH – n (%)
t(11;14) 1 (8) 1 (6) 5 (28) 8 (19) 15 (16)
del13q14 5 (38) 3 (17) 3 (17) 4 (9) 15 (16)
t(4;14) 2 (15) 5 (28) 5 (28) 1 (2) 13 (14)
del17p 3 (23) 5 (28) 0 (0) 4 (9) 12 (13)
High-risk cytogenetics† – n (%) 5 (38) 8 (44) 5 (28) 5 (12) 23 (50)
ISS stage – n (%)
I 6 (46) 6 (33) 8 (44) 23 (54) 43 (47)
II 6 (46) 8 (44) 8 (44) 16 (37) 38 (41)
III 1 (8) 4 (22) 2 (11) 4 (9) 11 (12)
ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; IMiD, immunomodulatory agent;
ISS, International Staging System; PI, proteasome inhibitor; sFLC, serum free light chains; SPEP/UPEP, serum protein electrophoresis/urine
protein electrophoresis.
*The status of 1 patient in Cohort 3 was unknown.
†High-risk cytogenetics defined as those patients with del17p or t(4;14).
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28 months (range, 04–140)], Cohort 4 had the highest PFS
at 46 months (range, 04+ to 173+). The PFS was higher in
those cohorts containing dex and in cohorts with higher
doses of ibrutinib.
Safety
All treated patients received doses ranging from 420 to
840 mg of daily ibrutinib with median durations of ibrutinib
treatment of 39, 26, 40, and 45 months in Cohort 1, 2, 3
and 4, respectively. No clinically significant differences in
safety were observed across cohorts or in comparison with
the established safety profile of ibrutinib (Table IV). Grade
≥3 treatment-emergent AEs were experienced by 57% of all
patients, and 29% experienced at least 1 serious AE. The
most frequent AEs (all grades) included diarrhoea (53%),
fatigue (43%), nausea (30%), anaemia (28%), thrombocy-
topenia (25%), muscle spasms (24%), cough (23%), insom-
nia (21%), upper respiratory tract infection (21%) and
arthralgia (20%). The incidence of fatigue and diarrhoea
were higher at the 840-mg dose level of ibrutinib. However,
these AEs were manageable with dose modification and/or
concomitant therapy, and neither led to discontinuation of
therapy. The rate of grade ≥3 haematological AEs was low,
with 16% anaemia, 11% thrombocytopenia and 2% neu-
tropenia. The most common grade ≥3 non-haematological
AE was pneumonia (7%). Rash was reported in 11 patients
(12%), with no grade ≥3 events. Intervention for rash was
required in 3 patients, with 1 patient requiring treatment
delay and a subsequent dose reduction. Grade 3 atrial fibril-
lation occurred in 1 patient (11%), and grade 2 atrial flutter
occurred in 1 patient (11%); neither of these patients had
ongoing medical history of atrial fibrillation or atrial flutter
at the time of study entry; no other atrial-associated events
of any grade were reported to date. Grade ≥3 acute kidney
injury occurred in 1 patient after administration of intra-
venous (IV) contrast. Dose reductions due to AEs were
reported in 9 patients (10%), with diarrhoea being the most
frequent reason for dose reduction occurring in 4 patients.
Of the 9 patients who had a dose reduction due to an AE, 3
patients subsequently discontinued treatment after the dose
reduction due to grade 3 vision blurred, grade 1 renal
impairment and grade 2 atrial flutter.
Patient disposition
At the time of analysis, 8% of patients were still on treatment
(1 patient in Cohort 1 and 6 in Cohort 4); all patients in
Cohorts 2 and 3 had discontinued treatment. The most com-
mon reason for discontinuation across the cohorts was PD
(60% overall). Other reasons for discontinuation across
cohorts included investigator discretion (13%) and AE (10%;
Table V). AEs leading to treatment discontinuation included
renal impairment (n = 2), with no other AEs occurring in
more than 1 patient. One patient in Cohort 1 remains on
study treatment (40 + cycles) at time of data cut-off, having
achieved an MR.
Discussion
To date, no targeted kinase inhibitors have been approved
for use in MM, despite the activity observed in other B-cell
Table II. Prior treatment exposure
Prior treatment regimen Cohort 1 (n = 13) Cohort 2 (n = 18) Cohort 3 (n = 18) Cohort 4 (n = 43) Overall (N = 92)
Median prior treatments – n (range) 3 (2–10) 4 (2–11) 3 (2–14) 4 (2–10) 3.5 (2–14)
Akylator – n (%) 13 (100) 17 (94) 14 (78) 40 (93) 84 (91)
Refractory 6 (46) 10 (56) 7 (39) 17 (40) 40 (43)
Thalidomide – n (%) 3 (23) 9 (50) 11 (61) 25 (58) 48 (52)
Refractory 1 (8) 5 (28) 5 (28) 6 (14) 17 (18)
Lenalidomide – n (%) 13 (100) 18 (100) 16 (89) 39 (91) 86 (93)
Refractory 9 (69) 14 (78) 9 (50) 27 (63) 59 (64)
Pomalidomide – n (%) 1 (8) 1 (6) 3 (17) 13 (30) 18 (20)
Refractory 1 (8) 0 (0) 3 (17) 12 (28) 16 (17)
Bortezomib – n (%) 13 (100) 18 (100) 15 (83) 39 (91) 85 (92)
Refractory 6 (46) 14 (78) 10 (56) 22 (51) 52 (57)
Carfilzomib – n (%) 1 (8) 5 (28) 6 (33) 14 (33) 26 (28)
Refractory 0 (0) 5 (28) 6 (33) 12 (28) 23 (25)
Monoclonal antibody – n (%) 1 (8) 4 (22) 2 (11) 4 (9) 12 (13)
Elotuzumab 0 (0) 2 (11) 1 (6) 0 (0) 3 (3)
Other* 1 (8) 2 (11) 1 (6) 5 (12) 9 (10)
Autologous stem cell transplant – n (%) 11 (85) 14 (78) 13 (72) 33 (77) 71 (77)
PI and IMiD – n (%) 13 (100) 18 (100) 15 (83) 40 (93) 86 (93)
IMiD, immunomodulatory agent; PI, proteasome inhibitor.
*Other includes investigational (BB-1091, BHQ880, BMS-936564, BT062; n = 4), rituximab (n = 2), nivolumab (n = 1), tositumomab (n = 1),
and SAR650984 (n = 1).
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malignancies. The BTK inhibitor ibrutinib, with or without
weekly dex, demonstrated promising activity and was well
tolerated in this heavily pre-treated RRMM population with
a median of 4 prior lines of therapy, including 74% of
patients who had disease that was refractory to their most
recent therapy. The AEs reported in this trial were consistent
with the safety profile of ibrutinib observed across other
B-cell malignancies (Burger et al, 2015; Wang et al, 2015;
Castillo et al, 2016; Falchi et al, 2016). The majority of AEs
reported were grades 1–2 and were managed with supportive
care. The incidence of grade ≥3 haematological AEs was con-
sistent with that expected in this patient population, and no
haematological AEs led to a dose reduction. Discontinuation
of ibrutinib and dex due to AEs was uncommon (10%), sug-
gesting that the treatment was generally well tolerated. Addi-
tionally, no increase in toxicity was observed with 840 mg of
daily ibrutinib when compared with the other cohorts. The
notable clinical activity demonstrated by the rate of sustained
SD (≥4 cycles) or response observed in approximately half
(51%) of the patients treated at 840 mg of daily ibrutinib in
combination with dex is encouraging given the nature of the
population evaluated. The highest activity was observed in
Cohort 4 (at the highest dose of ibrutinib administered),
with a 28% CBR, 5% ORR, 23% sustained SD and median
PFS of 46 months. Of the 58% of patients who were double
refractory to prior IMiDs and PIs and refractory to dex in
this cohort, responses were seen in 16%, indicating the
potential for benefit from ibrutinib and dex in this
population.
Most patients with MM eventually relapse and the clinical
benefit of treatment typically decreases with each subsequent
line of therapy (Cottini & Anderson, 2015; Usmani et al,
2016). Treatment selection for MM should focus on improv-
ing long-term outcomes. Median PFS with 840 mg of
Table III. Overall response by IMWG criteria
Response Cohort 1* (n = 13) Cohort 2 (n = 18) Cohort 3* (n = 18) Cohort 4 (n = 43)
PR – n (%) 0 (0) 1 (6) 0 (0) 2 (5)
MR – n (%) 1 (8) 0 (0) 0 (0) 10 (23)
SD ≥4 cycles – n (%) 1 (8) 4 (22) 6 (33) 10 (23)
SD <4 cycles – n (%) 5 (38) 10 (56) 5 (28) 12 (28)
PD – n (%) 5 (38) 2 (11) 4 (22) 6 (14)
NE – n (%) 0 (0) 1 (6) 1 (6) 0 (0)
CBR (≥MR) – % 8 6 0 28
ORR (≥PR) – % 0 6 0 5
CBR, clinical benefit rate; IMWG, International Myeloma Working Group; MR, minimal response; NE, not evaluable; ORR, overall response rate;
PD, progressive disease; PR, partial response; SD, stable disease.
Cohort 1 has 1 patient with unconfirmed PD; Cohort 3 has 2 patients with unconfirmed PD; Cohort 4 has 3 patients with unconfirmed PD.
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Fig 1. Progression-free survival by treatment
cohort. Cohort 4 showed a trend towards pro-
longed progression-free survival at the highest
dose of ibrutinib in combination with dexam-
ethasone in a heavily pre-treated population of
patients with relapsed/refractory multiple mye-
loma. Tick mark indicates censored patients.
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ibrutinib alone was 28 months compared with that for his-
torical controls of 19 months with high-dose dex alone
(Dimopoulos et al, 2015b).The efficacy of ibrutinib appeared
to be enhanced by the addition of LD dex, and compared
with ibrutinib alone, increased the median PFS. Although no
formal comparisons were made, increasing doses of ibrutinib
to 560 to 840 mg was associated with longer PFS, with
37 months in the 560 mg + dex cohort (Cohort 3) and
46 months in 840 mg + dex cohort (Cohort 4), demonstrat-
ing the clinical activity of ibrutinib. In this setting, other
agents have also shown to have enhanced activity in combi-
nation with dex. For example, carfilzomib + dex results in a
PFS that ranges from 62 to 187 months, while carfilzomib
alone ranged from 35 to 9 months; pomalidomide + dex
increased PFS by 28 to 116 months, while pomalidomide
alone was associated with a PFS of 46 to 95 months (Zou
et al, 2017).
Although disease stabilization is not defined as a formal
response to treatment, sustained SD in a heavily pretreated
RRMM population with manageable toxicities compared
with other treatment options suggests clinical benefit associ-
ated with ibrutinib treatment. Sustained disease stabilization
for at least 4 cycles was observed in 10 of the 43 patients
(23%) treated at the highest dose level of ibrutinib (840 mg)
in combination with dex, with 2 of these patients receiving
treatment and enjoying disease control beyond 1 year. In
addition, 20% of patients who were double refractory to cur-
rent backbone agents maintained disease stabilization for at
least 4 cycles, further suggesting the potential activity of ibru-
tinib in this otherwise difficult-to-treat population.
Preclinical study results provided evidence that BTK plays
a role in MM cell survival, with BTK overexpression
observed in the majority of malignant plasma cells from
patients with MM (Tai & Anderson, 2012; Bam et al, 2013).





























Haematological adverse events – n (%)
Anaemia 31 23 33 28 33 17 23 9 28 16
Thrombocytopenia 38 0 28 22 22 11 21 9 25 11
Neutropenia 8 0 0 0 17 6 2 2 5 2
Nonhaematological adverse events (>15%) – n (%)
Diarrhoea 38 0 44 0 56 6 63 2 53 2
Fatigue 23 0 39 0 50 11 49 0 43 2
Nausea 46 0 28 0 39 0 23 0 30 0
Muscle Spasms 31 0 33 0 17 0 21 0 24 0
Cough 31 0 17 0 11 0 28 0 23 0
Insomnia 8 0 28 0 6 0 28 0 21 0
Upper respiratory
tract infection
23 0 11 0 39 0 16 0 21 0
Arthralgia 23 0 22 0 22 0 16 0 20 0
Dizziness 15 0 22 0 11 0 21 0 18 0
Back pain 8 0 28 0 17 0 16 2 17 1
Pain in the extremity 8 0 28 6 0 0 23 2 17 2
Pyrexia 31 0 6 0 22 0 14 0 16 0
Dyspnea 15 0 22 0 11 6 14 2 15 2
Table V. Patient disposition











On treatment 1 (8) 0 (0) 0 (0) 6 (14) 7 (8)
Discontinued treatment 12 (92) 18 (100) 18 (100) 37 (86) 85 (92)
Progressive disease 6 (46) 11 (61) 12 (67) 26 (60) 55 (60)
Investigator discretion 3 (23) 6 (33) 2 (11) 1 (2) 12 (13)
Adverse event 1 (8) 0 (0) 3 (17) 5 (12) 9 (10)
Other* 2 (15) 1 (6) 1 (6) 5 (12) 9 (10)
*Includes patient withdrawal, noncompliance, and patient required prohibited concomitant medication.
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Moreover, the inhibition of BTK induces cytotoxicity in
human MM cells (Rushworth et al, 2013), providing a scien-
tific rationale for investigating ibrutinib as a therapeutic
option for MM as a new combination partner with a novel
mechanism of action. Preclinical studies have also demon-
strated that ibrutinib could act synergistically with common
backbone agents. Evidence of synergy between ibrutinib and
the IMiD lenalidomide and the PI bortezomib has been
observed in both MM patient cells and in MM cell lines, as
evidenced by an increased cytotoxicity of malignant plasma
cells (Rushworth et al, 2013). Additional preclinical data sug-
gest that both BTK inhibitors and IMiDs target the clono-
genic side populations of CD138neg cells, which are capable
of clonogenic growth, self-renewal and differentiation into
myeloma plasma cells (Yang et al, 2006; Jakubikova et al,
2011; Beauvais et al, 2016). Increased BTK expression in the
CD138neg side population cells is associated with clonogenic
growth, increased expression of pluripotent/embryonic stem
cell genes, and potential resistance to many standard mye-
loma treatments. In contrast, knockdown of BTK impeded
these effects in vitro and was able to restore bortezomib sen-
sitivity in BTK overexpressing cells (Yang et al, 2015).
The preliminary results of ibrutinib at 840 mg in combi-
nation with dex suggest clinical activity combined with a
favourable safety/tolerability profile. Continued exploration
of ibrutinib in triplet combinations with backbone agents,
including pomalidomide and bortezomib, is warranted to
potentially utilize synergistic effects observed preclinically.
These investigations are underway in studies PCYC-1138
(NCT02548962), PCYC-1139 (NCT02902965), and PCYC-
1119 (NCT01962792). In PCYC-1119, ibrutinib (840 mg) in
combination with carfilzomib and dex has already shown
early promising results with an initial ORR of 58%, a CBR
of 67%, and no dose-limiting toxicities during dose escala-
tion (Chari et al, 2015). Additionally, augmenting the effi-
cacy of immune therapies, such as monoclonal antibodies,
with selective inhibitors, such as ibrutinib, is emerging as an
area of great interest (Laubach & Richardson, 2015; van de
Donk et al, 2016). Given the safety and activity of ibrutinib
presented, future evaluation in combinations with next-gen-
eration, small-molecule inhibitors, monoclonal antibodies,
and checkpoint inhibitors in patients with RRMM will allow
evaluation of synergy across drug classes and with different
targets with the hope to identify regimens that will provide
greatest benefit to patients (Bianchi et al, 2015).
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